Trial Profile

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Venetoclax (Primary) ; Natural killer cell therapies
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions
Acronyms ADVENT-AML

Most Recent Events

12 Dec 2024 Trial approved by the FDA and institutional IRB. Activation planned for 2H 2023, according to trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition.
12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition.
26 Oct 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com